What is HC Wainwright’s Estimate for CRVS FY2028 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of $0.11 per share for the year, down from their prior forecast of $0.14. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.44 EPS.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective (up from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Corvus Pharmaceuticals Trading Up 0.6 %

Shares of CRVS stock opened at $3.37 on Thursday. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The stock’s fifty day simple moving average is $4.64 and its 200-day simple moving average is $6.06. The company has a market capitalization of $216.55 million, a price-to-earnings ratio of -3.62 and a beta of 0.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently modified their holdings of CRVS. Connor Clark & Lunn Investment Management Ltd. raised its stake in Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after purchasing an additional 53,809 shares during the last quarter. Nwam LLC bought a new stake in Corvus Pharmaceuticals during the 3rd quarter worth about $53,000. State Street Corp raised its position in shares of Corvus Pharmaceuticals by 48.2% during the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after acquiring an additional 57,943 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Corvus Pharmaceuticals during the third quarter worth approximately $265,000. Finally, XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals in the third quarter valued at about $74,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.